Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.33 |
| ▸ | RICTOR | Q6R327 | 8/20 | 0.33 |
| ▸ | MAPKAP1 | Q9BPZ7 | 8/20 | 0.33 |
| ▸ | MLST8 | Q9BVC4 | 8/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5931041 | 1.00 | MTOR (0.33) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL1688479 | 0.87 | MTOR (0.33) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL2688281 | 0.87 | GAA (0.34) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL1288847 | 0.87 | MTOR (0.33) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL2688192 | 0.87 | MTOR (0.33) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL1688532 | 0.87 | GAA (0.34) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL5934778 | 0.85 | MTOR (0.32) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL5934764 | 0.85 | MTOR (0.32) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL2051996 | 0.82 | MTOR (0.40) | MTORRICTORMAPKAP1MLST8CYP2C8 | |
| SCHEMBL2051995 | 0.82 | MTOR (0.40) | MTORRICTORMAPKAP1MLST8CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115848-A1 | Inhibitors of Polo-Like Kinase | PLK1, POLR2E, POLR2H | MTOR 594/4885RICTOR 2609/4885MAPKAP1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.